SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia293 Stable ...
BOSTON & SAN CARLOS, Calif.--(BUSINESS WIRE)--Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System ...
Cell line development is an essential step in the manufacture of biologics: drugs derived from living organisms, such as monoclonal antibodies, recombinant proteins and vaccines. In addition to this, ...
TrueSite TI™, the fourth generation of WuXia™ cell line platform, leverages targeted integration technique to streamline clone screening and guarantees expression stability. The platform has achieved ...
Aragen Biologics launched CHOMax™, a new cell line development and early manufacturing platform that the company says supports an integrated path from DNA to IND-enabling clinical supply for suitable ...
BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a cell line development partnership with Score ...
Synthetic bio company Asimov agreed to collaborate with Cytiva to provide customers with an integrated offering for optimized biologics production. Access includes Asimov’s CHO Edge cell line ...
Gibco CHOvantage GS Cell Line Development Kit delivers high productivity, streamlined timelines and royalty-free, clinical-stage licensing options to support scalable manufacturing Thermo Fisher ...
MATFORS, Sweden & LEXINGTON, Ky.--(BUSINESS WIRE)--NorthX Biologics and Demeetra today announced a strategic collaboration combining a best-in-class high-titer GS (-/-) CHO cell line with full freedom ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results